125 related articles for article (PubMed ID: 38251734)
21. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
22. The impact of demographics, socioeconomics, and health care access on melanoma outcomes.
Cortez JL; Vasquez J; Wei ML
J Am Acad Dermatol; 2021 Jun; 84(6):1677-1683. PubMed ID: 32783908
[TBL] [Abstract][Full Text] [Related]
23. [Increased survival in distant melanoma metastasis and the effect of treatments. Analysis of the disease course of patients with a survival of 2 years or more].
Garbe C
Hautarzt; 1996 Jan; 47(1):35-43. PubMed ID: 8835002
[TBL] [Abstract][Full Text] [Related]
24. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
25. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
26. Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients.
Tauceri F; Mura G; Roseano M; Framarini M; Ridolfi L; Verdecchia GM
Langenbecks Arch Surg; 2009 Nov; 394(6):1079-84. PubMed ID: 18317795
[TBL] [Abstract][Full Text] [Related]
27. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
28. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
29. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
30. Risk and Survival of Patients with Head and Neck Cutaneous Melanoma: National Perspective.
Al-Qurayshi Z; Hassan M; Srivastav S; Sperry S; Pagedar N; Hamner J; Kandil E
Oncology; 2017; 93(1):18-28. PubMed ID: 28423377
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Pflugfelder A; Eigentler TK; Keim U; Weide B; Leiter U; Ikenberg K; Berneburg M; Garbe C
PLoS One; 2011 Feb; 6(2):e16882. PubMed ID: 21359173
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
33. Disparities in melanoma presentation and overall survival among disaggregated Hispanic nationalities: A retrospective analysis of 2,517 patients in the National Cancer Database.
Kim DY; Behbahani S; Moncayo A; Trepanowski N; Hartman RI
Arch Dermatol Res; 2024 Jun; 316(7):377. PubMed ID: 38850418
[No Abstract] [Full Text] [Related]
34. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
35. Health Disparities Influence Childhood Melanoma Stage at Diagnosis and Outcome.
Hamilton EC; Nguyen HT; Chang YC; Eberth JM; Cormier J; Elting LS; Austin MT
J Pediatr; 2016 Aug; 175():182-7. PubMed ID: 27233520
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
38. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
[TBL] [Abstract][Full Text] [Related]
39. Impact of initial stage on metastatic melanoma survival.
Wilson MA; Zhong J; Rosenbaum BE; Utter K; Moran U; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Osman I
Melanoma Res; 2019 Jun; 29(3):281-288. PubMed ID: 31026246
[TBL] [Abstract][Full Text] [Related]
40. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
